A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Public ClinicalTrials.gov record NCT00094029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.
Study identification
- NCT ID
- NCT00094029
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2004 (Type not available)
- Primary completion
- Oct 2011 (Actual)
- Completion
- Oct 2011 (Actual)
- Last update posted
- Mar 9, 2012
2004 – 2011
United States locations
- U.S. sites
- 32
- U.S. states
- 14
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Duarte | California | 91010 | — |
| Pfizer Investigational Site | Pasadena | California | 91105 | — |
| Pfizer Investigational Site | San Francisco | California | 94115-1705 | — |
| Pfizer Investigational Site | Santa Monica | California | 90404 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010-2931 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32610 | — |
| Pfizer Investigational Site | Gainsville | Florida | 32610 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Tampa | Florida | 33612 | — |
| Pfizer Investigational Site | Niles | Illinois | 60714 | — |
| Pfizer Investigational Site | Park Ridge | Illinois | 60068 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | New Bedford | Massachusetts | 02741 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Farmington Hills | Michigan | 48334 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55455 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | Creve Coeur | Missouri | 63141 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1010 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1094 | — |
| Pfizer Investigational Site | Buffalo | New York | 14263 | — |
| Pfizer Investigational Site | New York | New York | 10022 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | The Bronx | New York | 10466 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Portland | Oregon | 97201 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Seattle | Washington | 98109 | — |
| Pfizer Investigational Site | Seattle | Washington | 98195 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00094029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00094029 live on ClinicalTrials.gov.